Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether cognitive impairment associated with
schizophrenia is attenuated by add-on roflumilast administration to second generation
antipsychotics (SGA) in participants with stable schizophrenia.